Literature DB >> 28912263

Hemodynamic Phenotyping of Pulmonary Hypertension in Left Heart Failure.

Robert Naeije1, Mario Gerges1, Jean-Luc Vachiery1, Sergio Caravita1, Christian Gerges1, Irene M Lang2.   

Abstract

Increased pulmonary venous pressure secondary to left heart disease is the most common cause of pulmonary hypertension (PH). The diagnosis of PH due to left heart disease relies on a clinical probability assessment followed by the invasive measurements of a mean pulmonary artery pressure (PAP) ≥25 mm Hg and mean wedged PAP (PAWP) >15 mm Hg. A combination of mean PAP and mean PAWP defines postcapillary PH. Postcapillary PH is generally associated with a diastolic pulmonary pressure gradient (diastolic PAP minus mean PAWP) <7 mm Hg, a transpulmonary pressure gradient (mean PAP minus mean PAWP) <12 mm Hg, and pulmonary vascular resistance ≤3 Wood units (WU). This combination of criteria defines isolated postcapillary PH. Postcapillary PH with elevated vascular gradients and pulmonary vascular resistance defines combined post- and precapillary PH (Cpc-PH). Postcapillary PH is associated with a decreased survival in proportion to increased pulmonary vascular gradients, decreased pulmonary arterial compliance, and reduced right ventricular function. The Cpc-PH subcategory occurs in 12% to 13% of patients with PH due to left heart disease. Patients with Cpc-PH have severe PH, with higher diastolic pulmonary pressure gradient, transpulmonary pressure gradient, and pulmonary vascular resistance and more pronounced ventilatory responses to exercise, lower pulmonary arterial compliance, depressed right ventricular ejection fraction, and shorter life expectancy than isolated postcapillary PH. Cpc-PH bears similarities to pulmonary arterial hypertension. Whether Cpc-PH is amenable to therapies targeting the pulmonary circulation remains to be tested by properly designed randomized controlled trials.
© 2017 American Heart Association, Inc.

Entities:  

Keywords:  ejection fraction; heart failure; pulmonary compliance; pulmonary hypertension; pulmonary vascular gradient; pulmonary vascular resistance; right ventricle

Mesh:

Year:  2017        PMID: 28912263     DOI: 10.1161/CIRCHEARTFAILURE.117.004082

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  22 in total

Review 1.  Pulmonary Hypertension Due to Left Heart Disease: an Update.

Authors:  Mandar A Aras; Mitchell A Psotka; Teresa De Marco
Journal:  Curr Cardiol Rep       Date:  2019-05-27       Impact factor: 2.931

2.  Haemodynamics to predict outcome in pulmonary hypertension due to left heart disease: a meta-analysis.

Authors:  Sergio Caravita; Céline Dewachter; Davide Soranna; Sandy Carolino D'Araujo; Amina Khaldi; Antonella Zambon; Gianfranco Parati; Antoine Bondue; Jean-Luc Vachiéry
Journal:  Eur Respir J       Date:  2018-04-04       Impact factor: 16.671

Review 3.  Pulmonary Artery Denervation: Update on Clinical Studies.

Authors:  Hang Zhang; Shao-Liang Chen
Journal:  Curr Cardiol Rep       Date:  2019-09-05       Impact factor: 2.931

4.  Pulmonary Hypertension Subtypes and Mortality in CKD.

Authors:  Daniel L Edmonston; Kishan S Parikh; Sudarshan Rajagopal; Linda K Shaw; Dennis Abraham; Alexander Grabner; Matthew A Sparks; Myles Wolf
Journal:  Am J Kidney Dis       Date:  2019-11-12       Impact factor: 8.860

5.  How does severe functional mitral regurgitation redefined by European guidelines affect pulmonary vascular resistance and hemodynamics in heart transplant candidates?

Authors:  Zübeyde Bayram; Cem Doğan; Rezzan Deniz Acar; Süleyman Efe; Özgür Yaşar Akbal; Fatih Yılmaz; Büşra Güvendi Şengör; Ahmet Karaduman; Samet Uysal; Ali Karagöz; Çağatay Önal; Mehmet Kaan Kırali; Cihangir Kaymaz; Nihal Özdemir
Journal:  Anatol J Cardiol       Date:  2021-06       Impact factor: 1.596

6.  Use of plasma late on cardiopulmonary bypass in patients undergoing left ventricular assist device implantation.

Authors:  James A Nelson; Juan C Diaz Soto; Matthew A Warner; John M Stulak; Phillip J Schulte; Timothy J Weister; William J Mauermann; Mark M Smith
Journal:  Artif Organs       Date:  2021-08-24       Impact factor: 2.663

Review 7.  Ambulatory factors influencing pulmonary artery pressure waveforms and implications for clinical practice.

Authors:  Amit Alam; Rita Jermyn; Ioannis Mastoris; Leslie Steinkamp; Arvind Bhimaraj; Andrew J Sauer
Journal:  Heart Fail Rev       Date:  2022-05-19       Impact factor: 4.654

8.  Frataxin deficiency promotes endothelial senescence in pulmonary hypertension.

Authors:  Miranda K Culley; Jingsi Zhao; Yi Yin Tai; Ying Tang; Dror Perk; Vinny Negi; Qiujun Yu; Chen-Shan C Woodcock; Adam Handen; Gil Speyer; Seungchan Kim; Yen-Chun Lai; Taijyu Satoh; Annie Mm Watson; Yassmin Al Aaraj; John Sembrat; Mauricio Rojas; Dmitry Goncharov; Elena A Goncharova; Omar F Khan; Daniel G Anderson; James E Dahlman; Aditi U Gurkar; Robert Lafyatis; Ahmed U Fayyaz; Margaret M Redfield; Mark T Gladwin; Marlene Rabinovitch; Mingxia Gu; Thomas Bertero; Stephen Y Chan
Journal:  J Clin Invest       Date:  2021-06-01       Impact factor: 14.808

9.  Understanding Longitudinal Changes in Pulmonary Vascular Resistance After Left Ventricular Assist Device Implantation.

Authors:  Gaurav Gulati; Robin Ruthazer; David Denofrio; Amanda R Vest; David Kent; Michael S Kiernan
Journal:  J Card Fail       Date:  2021-01-12       Impact factor: 5.712

10.  Pediatric Pulmonary Hypertension: Definitions, Mechanisms, Diagnosis, and Treatment.

Authors:  Devashis Mukherjee; Girija G Konduri
Journal:  Compr Physiol       Date:  2021-06-30       Impact factor: 8.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.